November 1, 2022
WellSIM is awarded an SBIR grant by NIH to develop a rapid and highly sensitive approach for early diagnosis of Alzheimer's Disease based on its ExoDot platform.
oCTOBER 1, 2022
WellSIM has moved to Qbay Center in San Jose, CA.
Q Bay Center is a 112,232 sqft diversified workspace for startups and growing companies, including 15 bio-innovative labs designed to accelerate high-potential life science startups.
May 25, 2022
WellSIM's technology "QUIT SARS-CoV-2" for rapid and highly sensitive detection of SARS-CoV-2 virus is published in Science Advances, entitled "Quantitative and Ultrasensitive In-situ Immunoassay Technology for SARS-CoV-2 Detection in Saliva". This project was supported by NIH Rapid Acceleration of Diagnostics (RADx) program.
August 15, 2020
WellSIM has been selected as part of the NIH Rapid Acceleration of Diagnostics (RADx) program in response to the 2019 Novel Coronavirus (COVID-19).
To fight against COVID-19, WellSIM is developing a novel platform (originally developed for exosome isolation and quantification), for on-site rapid (<20 min) and sensitive (<300 copies/mL viral load) detection of SARS-CoV-2 viral antigens, which can be performed at the primary care settings and improve the timely detection of COVID-19 infection.
June 23, 2020
Illumina, Inc. has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
WellSIM is proud to join the 11th funding cycle of Illumina Accelerator!